Showing 761 - 780 results of 52,184 for search '"glucose"', query time: 0.21s Refine Results
  1. 761
  2. 762

    Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada by Hamza Alshannaq, John J Isitt, Richard F Pollock, Gregory J Norman, Greg Cogswell, Peter M Lynch, Stephane Roze

    Published 2023-09-01
    “…Aim: Clinical trials and real-world data for Type 2 diabetes have shown that real-time continuous glucose monitoring (rt-CGM) lowers glycated hemoglobin (A1c) and reduces hypoglycemia relative to self-monitoring of blood glucose (SMBG). …”
    Article
  3. 763
  4. 764
  5. 765
  6. 766

    Differences in the impact of impaired glucose status on clinical outcomes in younger and older adults: Over a decade of follow-up in the Tehran lipid and glucose study by Samaneh Asgari, Soroush Masrouri, Davood Khalili, Fereidoun Azizi, Farzad Hadaegh

    Published 2022-10-01
    “…The age-specific (<60 and ≥60 years; minimum p-value for interaction = 0.001) multivariable-adjusted Cox regression was done to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) of the impaired glucose status including impaired fasting glucose (IFG) vs. normal fasting glucose (NFG), impaired glucose tolerance (IGT) vs. normal glucose tolerance (NGT), and IFG&IGT vs. …”
    Get full text
    Article
  7. 767
  8. 768

    The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes by Masahiko Iwamoto, Tetsuya Kubota, Yoshitaka Sakurai, Nobuhiro Wada, Seiji Shioda, Toshimasa Yamauchi, Takashi Kadowaki, Naoto Kubota

    Published 2022-08-01
    “…Abstract Epidemiological and animal studies have revealed that sodium‐glucose cotransporter 2 (SGLT2) inhibitors suppress cardiovascular events in subjects with type 2 diabetes and atherosclerosis in animal models of diabetes. …”
    Get full text
    Article
  9. 769

    Failure of glucose to elicit a normal secretory response in fetal pancreatic beta cells results from glucose insensitivity of the ATP-regulated K+ channels. by Rorsman, P, Arkhammar, P, Bokvist, K, Hellerström, C, Nilsson, T, Welsh, M, Welsh, N, Berggren, P

    Published 1989
    “…However, as judged from measurements of both glucose oxidation and glucose utilization, glucose metabolism was impaired in fetal beta cells. …”
    Journal article
  10. 770

    Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. by Hill, N, Oliver, N, Choudhary, P, Levy, J, Hindmarsh, P, Matthews, D

    Published 2011
    “…METHODS: Seventy-eight subjects without diabetes having a fasting plasma glucose of <120 mg/dL (6.7 mmol/L) underwent up to 72 h of continuous glucose monitoring (CGM) with a Medtronic Minimed (Northridge, CA) CGMS(®) Gold device. …”
    Journal article
  11. 771

    Accumulation of 2-deoxy-D-glucose-6-phosphate as a measure of glucose uptake in the isolated perfused heart: a 31P NMR study. by Hopkins, J, Radda, G, Veech, R, Clarke, K

    Published 2004
    “…The accumulation of 2-deoxy-D-glucose-6-phosphate (2DG6P), detected using 31P NMR spectroscopy, has been used as a measure of the rate of glucose uptake, yet the accuracy of this measurement has not been verified. …”
    Journal article
  12. 772

    Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups by Hill, N, Oliver, N, Choudhary, P, Levy, J, Hindmarsh, P, Matthews, DR

    Published 2011
    “…Methods: Seventy-eight subjects without diabetes having a fasting plasma glucose of <120 mg/dL (6.7 mmol/L) underwent up to 72 h of continuous glucose monitoring (CGM) with a Medtronic Minimed (Northridge, CA) CGMS® Gold device. …”
    Journal article
  13. 773
  14. 774

    Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. by Califf, R, Boolell, M, Haffner, S, Bethel, M, McMurray, J, Duggal, A, Holman, R

    Published 2008
    “…Patients with impaired glucose tolerance (IGT) have increased risk for developing type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). …”
    Journal article
  15. 775

    Continuous glucose monitoring system versus self-monitoring blood glucose in type 1 diabetes children (RoSEC) : a randomized controlled trial by Helmi, Muhd Alwi Muhd

    Published 2020
    “…Objectives The primary and secondary objectives were to compare the glycaemic control and frequency of hypoglycaemia between Continuous Glucose Monitoring System (CGMS) and Self-Monitoring Blood Glucose (SMBG). …”
    Get full text
    Thesis
  16. 776
  17. 777
  18. 778
  19. 779
  20. 780